IS2599B - 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess - Google Patents

3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Info

Publication number: IS2599B
Authority: IS; Iceland
Prior art keywords: phenylsulfonyl; piperazin; quinoline; pharmaceutically acceptable; acceptable derivatives
Prior art date: 2002-03-27

Application number

IS7470A

Other languages

English (en)

Other versions

IS7470A (is

Inventor

Mahmood Ahmed

Christopher Norbert Johnson

Martin C Jones

Gregor James Macdonald

Stephen Frederick Moss

Mervyn Thompson

Charles Edward Wade

David Witty

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-27

Filing date

2004-09-24

Publication date

2010-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2599(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-27 Priority claimed from GB0207289A external-priority patent/GB0207289D0/en

2002-11-04 Priority claimed from GB0225678A external-priority patent/GB0225678D0/en

2004-09-24 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-09-24 Publication of IS7470A publication Critical patent/IS7470A/is

2010-04-15 Publication of IS2599B publication Critical patent/IS2599B/is

Links

JJZFWROHYSMCMU-UHFFFAOYSA-N 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline Chemical compound C=1N=C2C(N3CCNCC3)=CC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 JJZFWROHYSMCMU-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)

IS7470A 2002-03-27 2004-09-24 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess IS2599B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0207289A GB0207289D0 (en)	2002-03-27	2002-03-27	Novel compounds
GB0225678A GB0225678D0 (en)	2002-11-04	2002-11-04	Novel compounds
PCT/EP2003/003197 WO2003080580A2 (en)	2002-03-27	2003-03-25	Quinoline derivatives and their use as 5-ht6 ligands

Publications (2)

Publication Number	Publication Date
IS7470A IS7470A (is)	2004-09-24
IS2599B true IS2599B (is)	2010-04-15

Family

ID=28456035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7470A IS2599B (is)	2002-03-27	2004-09-24	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Country Status (27)

Country	Link
US (5)	US7452888B2 (is)
EP (2)	EP1497266B1 (is)
JP (2)	JP4455064B2 (is)
KR (1)	KR101020399B1 (is)
CN (1)	CN1315809C (is)
AR (1)	AR039127A1 (is)
AT (1)	ATE398108T1 (is)
AU (1)	AU2003219103B2 (is)
BR (1)	BRPI0308696B8 (is)
CA (1)	CA2479786C (is)
CY (2)	CY1108313T1 (is)
DE (1)	DE60321558D1 (is)
DK (2)	DK1497266T3 (is)
ES (2)	ES2386828T3 (is)
IL (2)	IL164108A0 (is)
IS (1)	IS2599B (is)
MX (1)	MXPA04009318A (is)
MY (1)	MY138836A (is)
NO (1)	NO329319B1 (is)
NZ (1)	NZ535239A (is)
PL (1)	PL209872B1 (is)
PT (2)	PT1497266E (is)
RU (1)	RU2309154C9 (is)
SI (2)	SI1497266T1 (is)
TW (1)	TWI268928B (is)
WO (1)	WO2003080580A2 (is)
ZA (1)	ZA200407320B (is)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1497266T1 (sl) *	2002-03-27	2008-10-31	Glaxo Group Ltd	Derivati kinolina in njihova uporaba kot ligandi 5-ht6
PL378120A1 (pl)	2003-02-14	2006-03-06	Wyeth	Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy
CA2515571A1 (en)	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
EP1558582B1 (en)	2003-07-22	2005-12-21	Arena Pharmaceuticals, Inc.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0320320D0 (en) *	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en)	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en) *	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
GB0322629D0 (en) *	2003-09-26	2003-10-29	Glaxo Group Ltd	Novel compound
GB0407025D0 (en) *	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en) *	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0425548D0 (en) *	2004-11-19	2004-12-22	Glaxo Group Ltd	Radiolabelled ligands
GB0426313D0 (en) *	2004-12-01	2005-01-05	Merck Sharp & Dohme	Therapeutic agents
CN101189208A (zh)	2005-06-02	2008-05-28	弗·哈夫曼-拉罗切有限公司	作为gaba-b增强剂的3-甲磺酰基喹啉
CA2616473A1 (en)	2005-07-27	2007-03-08	F. Hoffmann-La Roche Ag	4-aryloxy quinoline derivatives as 5-ht6 modulators
GB0519765D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519760D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519758D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process
ATE444069T1 (de) *	2005-12-20	2009-10-15	Richter Gedeon Nyrt	Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
KR20090006148A (ko)	2006-04-05	2009-01-14	와이어쓰	5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체
MX2009006077A (es)	2007-01-08	2009-06-17	Suven Life Sciences Ltd	Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
EP2137162B1 (en) *	2007-03-15	2018-08-01	Novartis AG	Organic compounds and their uses
WO2008113818A1 (en) *	2007-03-21	2008-09-25	Glaxo Group Limited	Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
BRPI0809081A2 (pt)	2007-03-23	2019-09-24	Abbott Gmbh & Co Kg	compostos de quinolina adequados para tratamento de distúrbios que respondem á modulação do receptor da serotonina 5-ht6
KR101162482B1 (ko)	2007-05-03	2012-07-03	수벤 라이프 사이언시스 리미티드	아미노알콕시 아릴술폰아미드 화합물 및 ５-ｈｔ６ 리간드로서의 그의 용도
ES2392905T3 (es) *	2007-06-18	2012-12-14	Richter Gedeon Nyrt.	Derivados de sulfonil-quinolina
KR20100039300A (ko) *	2007-08-07	2010-04-15	애보트 게엠베하 운트 콤파니 카게	세로토닌 5-ｈｔ6 수용체의 조절에 반응하는 장애를 치료하는데 적합한 퀴놀린 화합물
DK2200980T3 (da)	2007-10-26	2011-11-21	Suven Life Sciences Ltd	Aminoarylsulfonamidforbindelser og deres anvendelse som 5-HT6-ligander
EP2254564A1 (en)	2007-12-12	2010-12-01	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
MX2010008778A (es) *	2008-02-15	2010-08-30	Hoffmann La Roche	Derivados de 3-alquil-piperazina y usos de la misma.
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en)	2008-07-18	2010-02-18	Novartis Ag	Organic Compounds as Smo Inhibitors
US8318725B2 (en)	2008-09-17	2012-11-27	Suven Life Sciences Limited	Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
HRP20130721T1 (en)	2008-09-17	2013-09-30	Suven Life Sciences Limited	Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
SG10201403696UA (en)	2009-06-29	2014-10-30	Agios Pharmaceuticals Inc	Therapeutic compounds and compositions
CN102844304B (zh) *	2010-01-04	2014-12-31	日本曹达株式会社	含氮杂环化合物以及农园艺用杀菌剂
AU2010340745B2 (en)	2010-01-05	2014-11-20	Suven Life Sciences Limited	Sulfone compounds as 5-HT6 receptor ligands
RU2443697C1 (ru) *	2010-12-21	2012-02-27	Александр Васильевич Иващенко	Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) *	2011-01-24	2013-04-03	이화여자대학교 산학협력단	5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es)	2011-05-20	2013-12-11	Nippon Soda Co	Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
AU2012321345B2 (en)	2011-10-03	2016-03-17	The University Of Utah Research Foundation	Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) *	2012-10-25	2013-12-10	Андрей Александрович Иващенко	(3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
US9302992B2 (en)	2013-04-02	2016-04-05	Annji Pharmaceutical Co., Ltd.	Multifunctional quinoline derivatives as anti-neurodegenerative agents
WO2014163622A1 (en)	2013-04-02	2014-10-09	Annji Pharmaceutical Co., Ltd.	Multifunctional quinoline derivatives as anti-neurodegenerative agents
KR20180021693A (ko) *	2015-05-07	2018-03-05	엑소반트 사이언시즈 게엠베하	신경퇴행성 질환을 치료하는 조성물 및 방법
HK1245660A1 (zh)	2015-06-12	2018-08-31	Axovant Sciences Gmbh	有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en)	2015-07-15	2017-01-19	Axovant Sciences Ltd.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
AR106515A1 (es)	2015-10-29	2018-01-24	Bayer Cropscience Ag	Sililfenoxiheterociclos trisustituidos y análogos
JP7027318B2 (ja) *	2016-02-05	2022-03-01	ファーネクスト	神経障害の新規の併用療法
WO2017157929A1 (en) *	2016-03-14	2017-09-21	AbbVie Deutschland GmbH & Co. KG	Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CN108290842B (zh) *	2016-05-27	2021-04-06	深圳市塔吉瑞生物医药有限公司	一种取代的喹啉化合物及其药物组合物
WO2018102824A1 (en) *	2016-12-02	2018-06-07	Axovant Sciences Gmbh	Methods for treating neurodegenerative disease
KR20210076224A (ko)	2019-12-13	2021-06-24	주식회사 에피바이오텍	퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) *	2020-12-09	2021-07-30	메디케어제약 주식회사	피페라진-퀴놀린 유도체의 제조방법

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US708469A (en) *	1901-08-27	1902-09-02	George Lafayette Caldwell	Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja)	1988-12-08	1990-10-25	Japan Synthetic Rubber Co Ltd	有機非線形光学素子
SI9200377A (en) *	1992-12-11	1994-06-30	Krka	Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en)	1993-01-06	1993-03-03	Minnesota Mining & Mfg	Photothermographic materials
GB9311790D0 (en)	1993-06-08	1993-07-28	Minnesota Mining & Mfg	Photothermographic materials
US5596001A (en) *	1993-10-25	1997-01-21	Pfizer Inc.	4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da)	1993-10-29	1993-10-29	Hempels Skibsfarve Fab J C	Marin struktur
US5576338A (en)	1995-02-15	1996-11-19	Merck Frosst Canada, Inc.	Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en)	1996-03-05	1996-03-28	Fujisawa Pharmaceutical Co., Ltd.	New compound
FR2750988B1 (fr)	1996-07-11	1998-09-18	Adir	Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DZ2376A1 (fr)	1996-12-19	2002-12-28	Smithkline Beecham Plc	Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US20010051719A1 (en) *	1996-12-19	2001-12-13	Smithkline Beecham P.L.C.	Novel compounds
DE59803962D1 (de)	1997-03-25	2002-06-06	Ciba Sc Holding Ag	Polycyclische Verbindungen
ES2207834T3 (es)	1997-04-22	2004-06-01	Janssen Pharmaceutica N.V.	Quino- y quinazolinas antagonistas del crf.
AU742739B2 (en)	1997-05-28	2002-01-10	Aventis Pharmaceuticals Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56 lck tyrosine kinases
US6376670B1 (en) *	1997-06-19	2002-04-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en)	1997-06-19	2000-08-15	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO1998057931A2 (en)	1997-06-19	1998-12-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en)	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
HUP0003073A3 (en)	1997-07-11	2002-10-28	Smithkline Beecham Plc	Benzenesulfonamide derivatives, process for producing them and their use as medicines
ATE236136T1 (de) *	1998-01-16	2003-04-15	Hoffmann La Roche	Benzosulfonderivate
GB9801392D0 (en) *	1998-01-22	1998-03-18	Smithkline Beecham Plc	Novel compounds
GB9803411D0 (en)	1998-02-18	1998-04-15	Smithkline Beecham Plc	Novel compounds
US6100291A (en)	1998-03-16	2000-08-08	Allelix Biopharmaceuticals Inc.	Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) *	1998-06-15	2001-06-26	Nps Allelix Corp.	Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818916D0 (en)	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
GB9819382D0 (en)	1998-09-04	1998-10-28	Cerebrus Ltd	Chemical compounds I
GB9820113D0 (en) *	1998-09-15	1998-11-11	Merck Sharp & Dohme	Therapeutic agents
US6403808B1 (en) *	1999-12-10	2002-06-11	Virginia Commonwealth University	Selective 5-HT6 receptor ligands
JP2002534512A (ja)	1999-01-15	2002-10-15	ノボノルディスクアクティーゼルスカブ	非ペプチドｇｌｐ−１アゴニスト
WO2000058313A1 (en)	1999-03-29	2000-10-05	Neurogen Corporation	4-substituted quinoline derivatives as gaba receptor ligands
ES2291024T4 (es) *	1999-04-21	2009-03-01	Nps Allelix Corp.	Compuestos de piperidina-indol con afinidad con 5-ht6.
AU4802500A (en)	1999-04-26	2000-11-10	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en)	1999-09-07	2006-09-29	Upjohn Co	Aminoalkoxy carbazoles for the treatment of cns diseases
WO2001032660A1 (en)	1999-11-05	2001-05-10	Nps Allelix Corp.	Compounds having 5-ht6 receptor antagonist activity
GB9926302D0 (en)	1999-11-05	2000-01-12	Smithkline Beecham Plc	Novel compounds
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en) *	2000-03-28	2001-10-30	Neurogen Corporation	4-substituted quinoline derivatives
PE20020063A1 (es)	2000-06-20	2002-01-30	Upjohn Co	Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv)	2000-07-21	2000-07-21	Pharmacia & Upjohn Ab	New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en)	2000-08-31	2000-10-18	Smithkline Beecham Plc	Novel compounds
US6576644B2 (en)	2000-09-06	2003-06-10	Bristol-Myers Squibb Co.	Quinoline inhibitors of cGMP phosphodiesterase
IL155163A0 (en)	2000-10-02	2003-10-31	Janssen Pharmaceutica Nv	Metabotropic glutamate receptor antagonists
AU9619301A (en)	2000-10-20	2002-04-29	Biovitrum Ab	2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
BR0115102B1 (pt)	2000-11-02	2013-11-26		Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
WO2002042293A1 (en)	2000-11-21	2002-05-30	Smithkline Beecham P.L.C.	Isoquinoline derivatives useful in the treatment of cns disorders
WO2002041889A2 (en)	2000-11-24	2002-05-30	Smithkline Beecham P.L.C.	Indolsulfonyl compounds useful in the treatment of cns disorders
ES2188344B1 (es)	2000-11-29	2004-09-16	Laboratorios Vita, S.A.	Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en)	2001-05-08	2001-06-27	Smithkline Beecham Plc	Novel compounds
PL367305A1 (en)	2001-06-07	2005-02-21	F.Hoffmann-La Roche Ag	New indole derivatives with 5-ht6 receptor affinity
EP1401812B1 (en)	2001-06-15	2006-06-28	F. Hoffmann-La Roche Ag	4-piperazinylindole derivatives with 5-ht6 receptor affinity
ITRM20010356A1 (it) *	2001-06-21	2002-12-23	Sigma Tau Ind Farmaceuti	"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
EP1411925A1 (en)	2001-08-03	2004-04-28	PHARMACIA & UPJOHN COMPANY	5-arylsulfonyl indoles having 5-ht6 receptor affinity
JP2005527463A (ja)	2001-08-07	2005-09-15	スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー	Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
CA2456250A1 (en)	2001-08-10	2003-02-20	F. Hoffmann-La Roche Ag	Arylsulfonyl derivatives with 5-ht6 receptor affinity
ES2398434T3 (es)	2001-08-31	2013-03-19	Novartis Ag	Isómeros ópticos de un metabolito de iloperidona
SE0103649D0 (sv)	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinoline compounds
JP2005518414A (ja)	2001-12-21	2005-06-23	スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー	ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用
GB0202679D0 (en) *	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
EP1471912A1 (en)	2002-02-05	2004-11-03	Glaxo Group Limited	Method of promoting neuronal growth
EP1487801B1 (en) *	2002-02-13	2006-04-19	Glaxo Group Limited	7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo¬d\|azepine derivatives with 5-ht6 receptor affinity for the treatment of cns disorders
DE10207844A1 (de)	2002-02-15	2003-09-04	Schering Ag	1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
EP1478361A2 (en)	2002-02-22	2004-11-24	PHARMACIA & UPJOHN COMPANY	Arylsulfone derivatives
SI1497266T1 (sl) *	2002-03-27	2008-10-31	Glaxo Group Ltd	Derivati kinolina in njihova uporaba kot ligandi 5-ht6
WO2003080608A2 (en)	2002-03-27	2003-10-02	Glaxo Group Limited	Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
DE10221183A1 (de)	2002-05-13	2003-12-04	Max Planck Gesellschaft	Phosphatidyl-oligo-glycerine und Strukturanaloga
DE60303376T2 (de)	2002-05-13	2006-11-16	F. Hoffmann-La Roche Ag	Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
AU2003237705B2 (en)	2002-06-05	2009-07-30	F. Hoffmann-La Roche Ag	1-sulfonyl-4-aminoalkoxy indole derivatives as 5-HT6-receptor modulators for the treatment of CNS-disorders
EA011581B1 (ru)	2002-06-20	2009-04-28	Биовитрум Аб (Пабл)	Конденсированные гетероциклические соединения, применимые для лечения ожирения и расстройств центральной нервной системы
JP4754821B2 (ja) *	2002-06-20	2011-08-24	プロキシマゲン・リミテッド	肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
PT1587788E (pt)	2002-09-17	2007-08-20	Hoffmann La Roche	''indoles 2,7-substituídos e a sua utilização como moduladores de 5-ht6''
NZ538047A (en)	2002-09-17	2007-10-26	Hoffmann La Roche	2,4-substituted indoles and their use as 5-HT6 modulators
DE60309498T2 (de)	2002-10-18	2007-08-30	F. Hoffmann-La Roche Ag	4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
EP1562918B1 (en)	2002-11-08	2008-01-16	F. Hoffmann-La Roche Ag	Substituted benzoxazinones and uses thereof
TWI284124B (en)	2002-12-03	2007-07-21	Hoffmann La Roche	Aminoalkoxyindoles
CA2515571A1 (en) *	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
RU2327689C2 (ru)	2003-03-03	2008-06-27	Ф.Хоффманн-Ля Рош Аг	2,5- замещенные тетрагидроизохинолины и фармацевтическая композиция для модуляции 5-нт6
TWI289141B (en)	2003-03-11	2007-11-01	Hoffmann La Roche F. Ag.	Quinolinone derivatives and uses thereof
GB0305575D0 (en) *	2003-03-11	2003-04-16	Glaxo Group Ltd	Novel compounds
GB0320320D0 (en)	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en)	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en)	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
GB0322629D0 (en)	2003-09-26	2003-10-29	Glaxo Group Ltd	Novel compound
GB0407025D0 (en)	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en)	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0422263D0 (en)	2004-10-07	2004-11-10	Glaxo Group Ltd	Novel compounds
GB0519765D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519760D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519758D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process

2003
- 2003-03-25 SI SI200331326T patent/SI1497266T1/sl unknown
- 2003-03-25 BR BRPI0308696A patent/BRPI0308696B8/pt not_active IP Right Cessation
- 2003-03-25 EP EP03714889A patent/EP1497266B1/en not_active Expired - Lifetime
- 2003-03-25 ES ES08157490T patent/ES2386828T3/es not_active Expired - Lifetime
- 2003-03-25 PL PL374378A patent/PL209872B1/pl unknown
- 2003-03-25 DK DK03714889T patent/DK1497266T3/da active
- 2003-03-25 DE DE60321558T patent/DE60321558D1/de not_active Expired - Lifetime
- 2003-03-25 ES ES03714889T patent/ES2307919T3/es not_active Expired - Lifetime
- 2003-03-25 AR ARP030101028A patent/AR039127A1/es not_active Application Discontinuation
- 2003-03-25 AU AU2003219103A patent/AU2003219103B2/en not_active Ceased
- 2003-03-25 MX MXPA04009318A patent/MXPA04009318A/es active IP Right Grant
- 2003-03-25 TW TW092106558A patent/TWI268928B/zh not_active IP Right Cessation
- 2003-03-25 MY MYPI20031054A patent/MY138836A/en unknown
- 2003-03-25 CN CNB038116448A patent/CN1315809C/zh not_active Expired - Fee Related
- 2003-03-25 AT AT03714889T patent/ATE398108T1/de active
- 2003-03-25 WO PCT/EP2003/003197 patent/WO2003080580A2/en not_active Ceased
- 2003-03-25 IL IL16410803A patent/IL164108A0/xx unknown
- 2003-03-25 NZ NZ535239A patent/NZ535239A/en not_active IP Right Cessation
- 2003-03-25 KR KR1020047015297A patent/KR101020399B1/ko not_active Expired - Fee Related
- 2003-03-25 JP JP2003578335A patent/JP4455064B2/ja not_active Expired - Fee Related
- 2003-03-25 RU RU2004131641/04A patent/RU2309154C9/ru not_active IP Right Cessation
- 2003-03-25 PT PT03714889T patent/PT1497266E/pt unknown
- 2003-03-25 US US10/509,078 patent/US7452888B2/en not_active Expired - Lifetime
- 2003-03-25 CA CA2479786A patent/CA2479786C/en not_active Expired - Fee Related
- 2003-03-25 SI SI200332178T patent/SI1956004T1/sl unknown
- 2003-03-25 DK DK08157490.7T patent/DK1956004T3/da active
- 2003-03-25 PT PT08157490T patent/PT1956004E/pt unknown
- 2003-03-25 EP EP08157490A patent/EP1956004B1/en not_active Expired - Lifetime
2004
- 2004-09-13 ZA ZA2004/07320A patent/ZA200407320B/en unknown
- 2004-09-14 IL IL164108A patent/IL164108A/en not_active IP Right Cessation
- 2004-09-24 IS IS7470A patent/IS2599B/is unknown
- 2004-10-25 NO NO20044588A patent/NO329319B1/no not_active IP Right Cessation
2008
- 2008-09-03 CY CY20081100943T patent/CY1108313T1/el unknown
- 2008-09-05 US US12/205,079 patent/US7601837B2/en not_active Expired - Fee Related
2009
- 2009-05-25 JP JP2009125459A patent/JP5091913B2/ja not_active Expired - Fee Related
- 2009-08-14 US US12/541,456 patent/US7799774B2/en not_active Expired - Fee Related
2010
- 2010-07-30 US US12/847,039 patent/US7977337B2/en not_active Expired - Fee Related
2011
- 2011-06-03 US US13/152,356 patent/US8236947B2/en not_active Expired - Fee Related
2012
- 2012-09-05 CY CY20121100804T patent/CY1113306T1/el unknown

Also Published As

Publication number	Publication date
US20100305107A1 (en)	2010-12-02
US20050124628A1 (en)	2005-06-09
AU2003219103B2 (en)	2008-10-23
US7452888B2 (en)	2008-11-18
RU2309154C2 (ru)	2007-10-27
CN1656075A (zh)	2005-08-17
SI1956004T1 (sl)	2012-09-28
CN1315809C (zh)	2007-05-16
ZA200407320B (en)	2005-11-30
CA2479786C (en)	2011-11-29
JP2009235080A (ja)	2009-10-15
EP1497266B1 (en)	2008-06-11
KR101020399B1 (ko)	2011-03-08
DK1497266T3 (da)	2008-10-06
IS7470A (is)	2004-09-24
RU2309154C9 (ru)	2016-09-27
JP5091913B2 (ja)	2012-12-05
US7601837B2 (en)	2009-10-13
US7977337B2 (en)	2011-07-12
KR20040094874A (ko)	2004-11-10
AU2003219103A1 (en)	2003-10-08
WO2003080580A2 (en)	2003-10-02
SI1497266T1 (sl)	2008-10-31
CA2479786A1 (en)	2003-10-02
HK1074439A1 (en)	2005-11-11
CY1113306T1 (el)	2016-04-13
DE60321558D1 (de)	2008-07-24
EP1956004A1 (en)	2008-08-13
NO329319B1 (no)	2010-09-27
MY138836A (en)	2009-07-31
RU2004131641A (ru)	2005-06-27
PT1497266E (pt)	2008-09-10
IL164108A (en)	2010-05-31
US20090036682A1 (en)	2009-02-05
JP4455064B2 (ja)	2010-04-21
DK1956004T3 (da)	2012-08-06
US20090298841A1 (en)	2009-12-03
JP2005531518A (ja)	2005-10-20
EP1956004B1 (en)	2012-06-13
MXPA04009318A (es)	2005-01-25
EP1497266A2 (en)	2005-01-19
TW200403224A (en)	2004-03-01
ATE398108T1 (de)	2008-07-15
BR0308696A (pt)	2005-01-25
CY1108313T1 (el)	2014-02-12
BRPI0308696A8 (pt)	2017-04-11
BRPI0308696B8 (pt)	2021-05-25
AR039127A1 (es)	2005-02-09
TWI268928B (en)	2006-12-21
IL164108A0 (en)	2005-12-18
US20110237792A1 (en)	2011-09-29
PT1956004E (pt)	2012-08-31
NO20044588L (no)	2004-10-25
BRPI0308696B1 (pt)	2019-07-16
PL209872B1 (pl)	2011-10-31
ES2307919T3 (es)	2008-12-01
NZ535239A (en)	2008-03-28
ES2386828T3 (es)	2012-08-31
WO2003080580A3 (en)	2004-02-05
US7799774B2 (en)	2010-09-21
US8236947B2 (en)	2012-08-07
PL374378A1 (en)	2005-10-17

Publication	Publication Date	Title
NO2022041I1 (no)	2022-10-03	Dapagliflozin og farmasøytisk akseptable salter derav - forlenget SPC
IS7948A (is)	2005-07-20	Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
LUC00127I1 (fr)	2019-09-19	Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92517I2 (fr)	2014-10-13	Delamanide et ses dérivés pharmaceutiquement acceptables
NO20041975D0 (no)	2004-05-13	Bicyklisk oksopyridin og oksopyrimidinderivater
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
DE60319951D1 (de)	2008-05-08	Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
LU92513I2 (fr)	2015-11-02	Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
DK1556385T3 (da)	2010-06-14	Heterocyclocarboxamid-derivater
DE60330372D1 (de)	2010-01-14	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK2248807T3 (da)	2013-08-26	N-Phenyl-2-pyrimidinaminderivater
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20052524D0 (no)	2005-05-26	Aminerte isofiavonoidderivater og anvendelse derav
DK1513835T3 (da)	2006-12-27	Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da)	2010-08-09	Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DE60307512D1 (de)	2006-09-21	3h-chinazoline -4-on derivaten
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
ATE423771T1 (de)	2009-03-15	Tetrahydrochinolinderivate
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
DK1392670T3 (da)	2005-08-08	Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
EP1499338A4 (en)	2008-06-18	7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES
IS7906A (is)	2005-06-22	Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls